BioMarin Pharmaceutical Inc. BMRN announced interim data from part 2 portion of an ongoing dose escalation phase I/II study on investigational enzyme replacement therapy, BMN 250, currently developed ...

BlackRock 2037 Municipal Target Term Trust offers primarily tax-free income through a diversified muni bond portfolio. BMN's modest leverage with the Fed cutting rates puts the fund in a unique ...

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Building up an investment case requires looking at a stock holistically.

The Company recently initiated an open-label phase 1/2 study to evaluate the safety, efficacy and tolerability of a single intravenous administration of BMN 307. The Food and Drug Administration (FDA) ...

BioMarin Pharmaceutical is continuing to slim down its pipeline, this time ending work on a preclinical phenylketonuria (PKU) drug once touted as a potential successor to its approved med Palynziq.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The consolidation of the Spanish banking sector continues apace, after state-controlled Bankia agreed to take ...

The average one-year price target for Bannerman Energy (ASX:BMN) has been revised to $6.24 / share. This is an increase of 18.32% from the prior estimate of $5.27 dated February 1, 2026. The price ...

This trial is no longer recruiting patients. We hope to add results when they are available. This study is learning more about a new drug called BMN 673, which hasn’t been tested in people before. It ...